Sep 11, 2020

Atlas Genetics在D系列融资中筹集3500万美元 本文共517个字，阅读需2分钟 Atlas Genetics Ltd., a Bath, England, UK-based ultra-rapid Point-Of-Care molecular diagnostics company, closed $35m in Series D financing.Backers included existing investors Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation – JJDC, Inc., LSP, BB Biotech Ventures, RMI Partners and Technology Venture Partners and new investor Wondfo Biotech, a Chinese in vitro diagnostic company.The company intends to use the funds to finance the clinical trials and commercial launch of a second test for detection of both Chlamydia and Gonorrhoea, planned for regulatory approvals in the US around the end of 2017, further develop additional diagnostics menu, and to expand cartridge manufacturing capacity at Bespak, its cartridge manufacturing partner.Led by Dr John Clarkson, Chief Executive Officer, Atlas Genetics develops ultra-rapid POC diagnostic tests for infectious diseases. Its io® system is a novel molecular diagnostic platform for the ultra-rapid diagnosis of a broad range of infectious diseases based on a patent-protected electrochemical sensor technology. An integrated cartridge, which contains all reagents, is designed to receive an unprocessed clinical specimen. Each cartridge can detect up to 24 different genetic targets from a patient sample.The company also has a commercial office in Boston, MA.FinSMEs23/01/2017 Atlas Genetics Ltd.，一家总部位于英格兰巴斯的超快速护理点分子诊断公司，完成了3500万美元的D系列融资。投资方包括现有投资者诺华风险基金，康索医疗有限公司，强生创新-JJDC，Inc.，LSP，BB Biotech Ventures，RMI Partners and Technology Venture Partners，以及新投资者中国体外诊断公司Wondfo Biotech。该公司打算用这笔资金资助第二项检测衣原体和淋病的试验的临床试验和商业启动，该试验计划于2017年底左右在美国获得监管批准，进一步开发额外的诊断菜单，并扩大其药筒制造合作伙伴Bespak的药筒制造能力。在首席执行官John Clarkson博士的领导下，Atlas Genetics开发了针对传染病的超快速POC诊断测试。其IO®系统是一种新颖的分子诊断平台，基于受专利保护的电化学传感器技术，可对广泛的传染病进行超快速诊断。一个包含所有试剂的集成药筒被设计用于接收未处理的临床标本。每个盒可以从一个病人样本中检测多达24个不同的遗传靶点。该公司还在马萨诸塞州波士顿设有商业办事处。FINSMES23/01/2017 以上中文文本为机器翻译，存在不同程度偏差和错误；偶尔因源网页结构局限，内容无法一次完整呈现。请理解并参考原站原文阅读。